



COLORADO
BIOSCIENCE
ASSOCIATION

January 6, 2021

The Honorable Jason E. Kearns
Chairman
U.S. International Trade Commission
500 E Street, SW
Washington, DC 20436

Re: Certain plant-derived recombinant human serum albumins ("rHSA") and products containing same, ITC Docket No. 3513

Dear Chairman Kearns:

I respectfully submit these comments to the U.S. International Trade Commission in relation to the above-referenced proceeding. The Complainant, Ventria Bioscience Inc., is an important member of the Colorado life sciences community and has made major scientific contributions that are significant to the United States economy.

Ventria (which also operates as InVitria) is a privately held company based in Aurora, Colorado and Junction City, Kansas. Among other innovations, Ventria is a recognized leader in the field of plant-based expression of recombinant proteins. Ventria has invested enormous resources in developing and achieving commercial acceptance of this novel technology. Ventria's products are all developed and made in the United States. Notably, Ventria has placed a priority on attracting and hiring talent in the Midwest, and it works collaboratively with notable U.S. research institutions.

It is crucial to protect the U.S. biotechnology industry, and particularly companies like Ventria, from unfair interference by foreign actors. While my organization takes no position on the merits of the present case, this is precisely the type of situation that requires the ITC's close attention. If a violation is found, issuance of the requested remedies would appear to promote the U.S. public interest.

Thank you for considering this submission. Please feel free to contact me with any questions.

Sincerely,

A handwritten signature in blue ink that reads "Jennifer Jones Paton".

Jennifer Jones Paton
President & CEO
Colorado BioScience Association